SLC12A1
Basic information
Region (hg38): 15:48178438-48304078
Links
Phenotypes
GenCC
Source:
- antenatal Bartter syndrome (Supportive), mode of inheritance: AR
- Bartter disease type 1 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Bartter syndrome, antenatal, type 1 | AR | Renal | Sequelae can be lethal; Medical treatment of manifestations including hypokalemia and metabolic alkalosis (eg, with KCl supplementation, NSAIDs), as well as related findings such as nephrocalcinosis, can be beneficial | Renal | 3863906; 8457138; 3888887; 8640224; 9355073; 19513753; 20219833 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (58 variants)
- Bartter disease type 1 (10 variants)
- Nephrocalcinosis;Nephrolithiasis (1 variants)
- SLC12A1-related disorder (1 variants)
- Nephrolithiasis;Nephrocalcinosis (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC12A1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 202 | 208 | ||||
missense | 188 | 209 | ||||
nonsense | 30 | 33 | ||||
start loss | 0 | |||||
frameshift | 24 | 31 | ||||
inframe indel | 4 | |||||
splice donor/acceptor (+/-2bp) | 23 | 26 | ||||
splice region | 1 | 9 | 36 | 3 | 49 | |
non coding | 21 | 176 | 61 | 258 | ||
Total | 58 | 41 | 217 | 386 | 67 |
Highest pathogenic variant AF is 0.000315
Variants in SLC12A1
This is a list of pathogenic ClinVar variants found in the SLC12A1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-48201395-C-A | not specified | Uncertain significance (Jul 14, 2021) | ||
15-48201415-A-G | not specified | Uncertain significance (Jan 23, 2023) | ||
15-48201541-G-A | not specified | Uncertain significance (Sep 15, 2021) | ||
15-48207459-T-A | Likely benign (Mar 16, 2022) | |||
15-48207506-C-T | Benign (Jan 26, 2020) | |||
15-48207584-A-G | Bartter disease type 1 | Benign (Oct 03, 2020) | ||
15-48207607-A-C | Bartter disease type 1 | Uncertain significance (Jan 13, 2018) | ||
15-48207620-C-T | Bartter disease type 1 | Uncertain significance (Jan 13, 2018) | ||
15-48207652-G-T | Bartter disease type 1 | Likely benign (Jan 12, 2018) | ||
15-48207726-C-T | Likely benign (Jun 02, 2023) | |||
15-48207732-A-G | Uncertain significance (-) | |||
15-48207733-A-G | Uncertain significance (Dec 18, 2023) | |||
15-48207745-T-C | Uncertain significance (Aug 27, 2021) | |||
15-48207769-A-G | Inborn genetic diseases • SLC12A1-related disorder | Uncertain significance (Jun 11, 2021) | ||
15-48207770-T-C | Likely benign (Dec 23, 2023) | |||
15-48207778-G-A | Bartter disease type 1 | Conflicting classifications of pathogenicity (Jun 10, 2024) | ||
15-48207783-C-T | Pathogenic (Feb 23, 2023) | |||
15-48207790-G-A | Benign/Likely benign (Jan 31, 2024) | |||
15-48207791-T-C | Likely benign (Apr 11, 2023) | |||
15-48207807-C-G | Inborn genetic diseases | Uncertain significance (Oct 26, 2022) | ||
15-48207809-T-C | Likely benign (Dec 11, 2023) | |||
15-48207810-G-A | Inborn genetic diseases | Uncertain significance (May 28, 2024) | ||
15-48207829-A-G | Uncertain significance (Jun 04, 2022) | |||
15-48207837-A-G | Bartter disease type 1 | Uncertain significance (Jul 13, 2022) | ||
15-48207854-T-C | Likely benign (Mar 27, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SLC12A1 | protein_coding | protein_coding | ENST00000396577 | 26 | 112415 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
6.68e-17 | 0.984 | 125465 | 0 | 128 | 125593 | 0.000510 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.16 | 502 | 581 | 0.864 | 0.0000291 | 7188 |
Missense in Polyphen | 212 | 269.91 | 0.78545 | 3340 | ||
Synonymous | -0.603 | 222 | 211 | 1.05 | 0.0000119 | 2076 |
Loss of Function | 2.63 | 35 | 56.3 | 0.621 | 0.00000280 | 700 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00133 | 0.00132 |
Ashkenazi Jewish | 0.0000995 | 0.0000993 |
East Asian | 0.000437 | 0.000435 |
Finnish | 0.000464 | 0.000462 |
European (Non-Finnish) | 0.000462 | 0.000449 |
Middle Eastern | 0.000437 | 0.000435 |
South Asian | 0.000473 | 0.000457 |
Other | 0.000826 | 0.000816 |
dbNSFP
Source:
- Function
- FUNCTION: Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.;
- Pathway
- Diuretics Pathway, Pharmacodynamics;Polythiazide Action Pathway;Methyclothiazide Action Pathway;Bumetanide Action Pathway;Spironolactone Action Pathway;Eplerenone Action Pathway;Triamterene Action Pathway;Amiloride Action Pathway;Ethacrynic Acid Action Pathway;Quinethazone Action Pathway;Bendroflumethiazide Action Pathway;Chlorthalidone Action Pathway;Trichlormethiazide Action Pathway;Iminoglycinuria;Lysinuric Protein Intolerance;Blue diaper syndrome;Lysinuric protein intolerance (LPI);Cystinuria;Indapamide Action Pathway;Furosemide Action Pathway;Torsemide Action Pathway;Hartnup Disorder;Glucose Transporter Defect (SGLT2);Kidney Function;Glucose Transporter Defect (SGLT2);Metolazone Action Pathway;Hydrochlorothiazide Action Pathway;Cyclothiazide Action Pathway;Hydroflumethiazide Action Pathway;Chlorothiazide Action Pathway;Cation-coupled Chloride cotransporters;Transport of inorganic cations/anions and amino acids/oligopeptides;SLC-mediated transmembrane transport;Transport of small molecules
(Consensus)
Recessive Scores
- pRec
- 0.105
Intolerance Scores
- loftool
- 0.0632
- rvis_EVS
- -0.83
- rvis_percentile_EVS
- 11.49
Haploinsufficiency Scores
- pHI
- 0.559
- hipred
- Y
- hipred_score
- 0.651
- ghis
- 0.435
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.171
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Slc12a1
- Phenotype
- immune system phenotype; renal/urinary system phenotype; skeleton phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- ion transport;cell volume homeostasis;ion transmembrane transport;sodium ion transmembrane transport;chloride ion homeostasis;potassium ion homeostasis;sodium ion homeostasis;chloride transmembrane transport;potassium ion import across plasma membrane
- Cellular component
- plasma membrane;membrane;integral component of membrane;apical plasma membrane;extracellular exosome
- Molecular function
- sodium:potassium:chloride symporter activity;sodium ion transmembrane transporter activity;sodium:chloride symporter activity;potassium:chloride symporter activity